MedTrace Logo

The Effects of Mogroside Sweetener on Viral Load in TreatmenT Naive Genotype 1 (GT 1) Subjects CHC

NCT00926120 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2012-02-14

No results posted yet for this study

Summary

The purpose of this study is to determine if administering Mogroside Sweetener "PureLo" (the study substance) for 14 days will lower the hepatitis C viral load and liver function alanine aminotransferase (ALT) levels.

Conditions

  • Hepatitis C

Interventions

DIETARY_SUPPLEMENT

Mogroside sweetener (PureLo)

Mogroside sweetener administered at a dosage level of 5g every 6 hours for 14 days

Sponsors & Collaborators

  • The Geneva Foundation

    collaborator OTHER

  • Brooke Army Medical Center

    lead FED

Principal Investigators

  • Stephen A Harrison, MD · Brooke Army Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-12-31
Primary Completion
2009-04-30
Completion
2010-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00926120 on ClinicalTrials.gov